# Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

> **NCT02896582** · PHASE2 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 86 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Dexamethasone
- **DRUG:** Aracytine
- **DRUG:** Cisplatinum
- **DRUG:** Etoposide
- **DRUG:** Melphalan
- **DRUG:** Carmustine

## Key facts

- **NCT ID:** NCT02896582
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-29
- **Primary completion:** 2019-03
- **Final completion:** 2024-12-02
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896582, "Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02896582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*